Retinoids are potent inducers of cell cycle arrest and differentiation of numerous cell types, notably granulocytes. However the mechanisms by which retinoids mediate cell cycle arrest during differentiation remain unclear. We have utilised myeloid differentiation to characterise the molecular pathways that couple cell cycle withdrawal to terminal differentiation. Using primary cells from mice deficient for either the CDKi p27 Kip1
Introduction
The roles of retinoids during hematopoiesis, particularly granulopoiesis, have been recognised for many years. Most strikingly retinoids are powerful inducers of differentiation 1 . This effect is central to the use of all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL), a leukemia characterised by a chromosomal translocation always involving retinoic acid receptor (RAR , 2, 3 ).
Pharmacological doses of ATRA are able to relieve the repression caused by the fusion proteins via directly binding and activating them, promoting cell cycle arrest and differentiation of the leukaemic blasts 3 . However, the mechanisms by which ATRA mediates cell cycle arrest as well as differentiation remain unclear. An understanding of the molecular basis of this effect will provide important insights into how cell cycle withdrawal is coupled to terminal differentiation and how retinoids interact with the cell cycle.
The effects of retinoid ligands are mediated through direct binding to the ligand binding domain of RARs or retinoid X receptors (RXRs), members of the nuclear hormone receptor superfamily 4 . RARs heterodimerize with RXRs, and this heterodimer binds DNA at retinoic acid response elements (RARE) in the regulatory sequences of target genes. When unliganded, RAR/RXR heterodimers bind RARE and form repressive complexes through binding SMRT and NCo-R containing corepressor complexes 5 . Ligand binding triggers the release of the co-repressor complexes and co-activator complexes are recruited to the RAR/RXR dimer and activate gene transcription [6] [7] [8] . Three isotypes of RARs and RXRs have each been identified: , and , with each RAR isotype expressed as a number of isoforms 4 .
RAR and RAR are believed to be most important in the regulation of granulopoiesis 4, 9 . This is most strikingly demonstrated in progenitor assays of bone marrow cells derived from RAR 1 -/-RAR -/-mice. These cells displayed a block in
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From Walkley et al. 4 granulopoiesis at the myelocyte stage of development, revealing an absolute requirement for RAR mediated signalling in the terminal differentiation of granulocytes 9 .
Our understanding of the mechanism/s through which RAR mediates cell cycle arrest and differentiation of myeloid cells is a question of particular relevance.
Firstly, RAR , but not RAR or , has been found to be involved in the pathogenesis of myeloid leukemia 10 . RAR is involved in leukemia both as a fusion partner, most commonly involving PML in APL, and point mutations in the RAR protein have also been reported to result in retinoid resistance 11 . These data suggest a critical role for RAR -mediated signalling in regulating granulopoiesis. Secondly, related to the observations directly linking RAR to the pathogenesis of leukemia, is the development of high specificity RAR agonists as therapeutics 12 . The identification of the specific downstream effectors of RAR -mediated signalling and the ability to place these targets into molecular pathways allows insight into the mechanism of drug action of RAR -specific ligands and rational application of these compounds.
Cellular differentiation commonly involves a tight coupling of withdrawal from the cell cycle and the acquisition of specialised cell functions. Whilst the molecular mechanisms that regulate the cell cycle during mitotic cell division cycles have become increasingly clear, the mechanisms that regulate cell cycle withdrawal during differentiation remain poorly understood 13 . Several families of proteins have been identified that may play a role in cell cycle withdrawal during differentiation, including the Mad family of transcriptional repressors 14 and the Cip/Kip family of cyclindependent kinase inhibitors 13 . How proteins such as these co-operate during cell cycle withdrawal remains a critical question to our understanding of differentiation. . These studies, as well as studies in primary cells from mutant mice, implicate roles for both Mad1 and p27 Kip1 in regulating cell cycle exit during retinoid-induced granulocytic differentiation 17, 19 . In the current study we sought to determine the contributions of Mad1 and p27 Kip1 to retinoid-induced cell cycle withdrawal pathways during granulocytic differentiation.
In this report we demonstrate that both Mad1 and p27 Kip1 
Materials and Methods

Retinoid Ligands
All-trans Retinoic Acid (ATRA) was purchased from Sigma and was dissolved in DMSO and diluted with ethanol prior to use. The synthetic RAR -specific agonists
AGN194078
20 and AGN195183
20
, the RAR -specific antagonist AGN194301 21 and the pan-RAR antagonist AGN194310 22 were synthesised by Allergan Inc.
Mice p27
Kip1 mutant mice were kindly provided by Dr. J. Roberts
23
.
Mad1 mutant and
Mad1/p27 Kip1 double mutant mice have been previously described 17, 19 . All wild-type mice were derived from within the breeding colony. Retinoic acid receptor mutant mice (RAR and RAR ) have been previously described 24, 25 . Mice were used at 7 -12 weeks of age.
Isolation and expression profiling of immature and mature granulocyte populations.
Bone marrow from a wild-type mouse was collected, and prepared as described previously 26 . Samples were stained with PE anti-CD11b and FITC anti-Gr-1 Quantitative real-time PCR was performed following isolation of granulocyte fractions and on MPRO cells differentiated with AGN195183. Cells were lysed in Trizol reagent (Invitrogen) and RNA prepared using standard procedures. cDNA was prepared following DNase treatment using random primers and Superscript II reverse transcriptase (Invitrogen) as described by manufacturer. PCR was performed using quantitative real-time PCR, using the SYBR Green® dye detection method (Applied Biosystems). Primers were designed for Mad1, RAR , C/EBP and 2-microglobin cDNA using Primer Express software (Applied Biosystems).
Primary granulocyte cultures
Whole bone marrow (1 x 10 5 /mL) was cultured in DMEM containing 20% FBS (CSL), 15% BHK-SCF cell conditioned media (source of SCF, equivalent to 150ng/ml, gift from S.Collins), 1000U/ml rhG-CSF (Amgen) and either AGN195183 (10 -6 M), ATRA (10 -6 M) or Control (Ethanol). Cultures were FACS analysed after 3 days using CD11b/Gr-1 staining and morphologically.
Progenitor cell assays
Colony-forming cell (CFC) assays were performed using 3% methylcellulose-based media. Methylcellulose (3% in Iscove's Modified Dulbecco's Media, Gibco)
supplemented with 20% FBS, 2U/mL rHu erythropoietin (Janssen-Cilag, Sydney), 10% BHK-SCF cell conditioned, 1% X63Ag8-653-IL3 cell conditioned media 27 (source of IL-3; 1000U/ml) and 1% IL-6 cell conditioned media (source of IL6, 1000U/ml). Colonies were scored on day 7 of culture.
Where indicated retinoids were directly added at a final concentration of: ATRA (10 
Northern Analysis
Northern analysis was performed on total RNA extracted using Trizol reagent (Invitrogen). Following electrophoresis and transfer to nylon membrane (ImmobilonNy+, Millipore) membranes were probed using cDNA probes to Mad1, p27 Kip1 , C/EBP and GAPDH.
Generation of MPRO cell lines and C/EBP -ER MPRO cell lines.
MPROs were generated from whole bone marrow of mice of the appropriate genotype and maintained in culture as previously described 19, 28 . Retroviral infection of MPRO cell lines with either pBabe or pBabeC/EBP -ER was performed as described 17 . Infected cells were selected with 2µg/ml puromycin (Sigma) and maintained as bulk culture or cloned through 3% methylcellulose supplemented with 20% FCS and 1000U/mL GM-CSF. For all C/EBP -ER infections at least 3 independent infections were performed and at least 6 clones from each infection screened for phenotypic response. The soluble chromatin fraction was collected and 5µg of anti-C/EBP antibody added (sc-158). Samples, were incubated overnight at 4ºC with rotation. Immune complexes were retrieved, washed and eluted with buffer. Protein-DNA cross-links were reversed by incubation at 65ºC with NaCl. Samples were treated with proteinase K, DNA was recovered and ethanol precipitated with the inclusion of glycogen (0.02mg). DNA pellets were resuspended in TE buffer. PCR was conducted using quantitative real-time PCR, using the SYBR Green® dye detection method (Applied Biosystems). Primers were designed to encompass putative C/EBP consensus binding sites.
For
Statistical analyses
Statistical analyses were performed using an unpaired Student's two-tailed T test to assess differences between the means. The standard error of the mean was used to determine the deviation from the mean.
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Results
Expression of Mad1 and p27
Kip1 during terminal differentiation of primary granulocytes Utilising a well-characterised FACS based isolation strategy 26 , we isolated an immature granulocytic population (CD11b/Gr-1 dim ) and a mature granulocyte population (CD11b/Gr-1 bright ). We used these populations to analyse the expression of Mad1 and p27 Kip1 during terminal differentiation of granulocytes by western blotting. p27 Kip1 was detected in both the immature and mature granulocyte populations, with a significantly increased amount detected in the terminally differentiated mature cell population ( Fig 1A) . Mad1, as for p27 Kip1 , was present at low levels in the immature population and at higher levels in the differentiated mature cells ( Fig 1A) . Within the immature population we were unable to detect c-Myc , further confirming the specificity of the ligand and the interaction of RAR -dependent signalling pathways with Mad1.
Taken together these data implicate Mad1 as an important mediator of granulocytic differentiation in response to RAR -specific activation, but not of the effects of ATRA.
To determine if loss of p27 . This reduction in colony forming efficiency is due to retinoid-induced cell cycle arrest of progenitors, preventing colony formation.
To determine the (Fig 3C) . This increase contrasts with the reduction observed in transcript levels (Fig 3A) . Together these data demonstrate that RAR activated differentiation results in an increase in cellular p27 Kip1 protein, through post-transcriptional mechanisms.
Mad1 is directly induced by C/EBP , but not RAR .
To determine the effects of RAR on Mad1, we examined transcript levels following differentiation of MPRO cells. Mad1 transcript can be seen to increase at 2 days and significantly by 3 days after differentiation induction by RAR (Fig 4A) . and enforced expression of C/EBP in vivo in PML-RAR transgenic mice is able to overcome the block to differentiation and promote maturation of cells harbouring the transgene [42] [43] [44] . Utilising the MPRO cell line we generated cells containing a stably integrated 4-hydroxy-tamoxifen inducible C/EBP construct (C/EBP -ER). These cells differentiated into mature granulocytes upon activation of C/EBP , demonstrating that C/EBP can functionally replace retinoid agonists and induce differentiation in the MPRO cell line (see Fig 6A) .
Utilising these cells, we sought to determine if C/EBP was able to regulate expression of either p27 KIP1 or Mad1. Analysis of mRNA after activation of C/EBP in the presence and absence of cycloheximide revealed that, as with RAR , p27
Kip1 was not transcriptionally regulated by C/EBP during differentiation in these cells (data not shown). Mad1 transcript, however, was upregulated rapidly by 3 hours upon activation of C/EBP and this occurred in the presence of cycloheximide, suggesting direct regulation of the Mad1 transcription (Fig 4D) . This contrasts dramatically with the effects of RAR agonists on Mad1, where induction of Mad1 transcript begins at 48hrs (Fig 4A) . Confocal microscopy clearly demonstrated that Mad1 protein was induced as early as 14 hours after the induction of C/EBP and increased at 24 hours after activation (Fig 4E) . This induction did not occur in vector control infected cells, nor was Mad1 protein detectable at these time points during RAR agonist-induced differentiation of the MPRO cell line (Fig 4D and 4E accumulation of C/EBP on the consensus site most proximal to the first exon of Mad1 (Fig 5A and 5C ). This enrichment was specific for this site as other putative C/EBP consensus binding sites within 3 kb of the first exon of Mad1 were not significantly bound in vivo by C/EBP , nor was an unrelated promoter that does not For personal use only. on November 12, 2017. by guest www.bloodjournal.org From contain C/EBP consensus sites ( Fig 5A and 5C and mUBF promoter, supplemental data). This data provides a mechanism linking differentiation to the direct induction of the MYC-antagonist Mad1.
The RAR target gene C/EBP is unable to induce differentiation in Mad1
-/-p27
Kip1-/-MPROs.
We had previously reported a failure in cell cycle arrest and differentiation of Mad1 (Fig 7) .
It has previously been reported that p27
Kip1 is required to mediate the appropriate cell cycle withdrawal of oligodendrocyte precursor cells during differentiation and that this is a non-redundant role of p27 Kip146, 47 . Consistent with these reports, we detected a significant accumulation of p27 Kip1 protein during the differentiation of granulocytes, although the nature of this accumulation has not been fully elucidated in the current study. p27 . Cumulative data places C/EBP family members as central components during the switch from a proliferative state to an arrested differentiated cell type [49] [50] [51] [52] .
Recent data has demonstrated that C/EBP can interact with the cell cycle through a number of distinct mechanisms. C/EBP can directly regulate the cell cycle through The mechanisms through which differentiating agents such as retinoids are able to induce cell cycle arrest is of significance to the clinical application of these compounds. One of the characteristics of malignancy is the loss of the capacity to withdraw from the cell cycle, often accompanied by loss or mutation of the regulatory proteins for the G 1 -S phase transition of the cell cycle 56, 57 . Our study reveals that loss of genes that are important in the withdrawal from the cell cycle can directly impact on the efficacy of retinoids. RAR-specific retinoids are being developed and evaluated in the hope of improved specificity and a reduced side effect profile over conventional pan-RAR agonists 12, 58 . The identification of pathways specific for the distinct RARs, such as Mad1 and p27
Kip1 for RAR -mediated cell cycle arrest pathways, may allow a more rational application of these compounds. Our study also reveals that RAR -induced differentiation of granulocyte progenitors occurs independent of Mad1 and p27 Kip1 status, highlighting potential differences in target genes amongst the RARs that may be able to be therapeutically exploited. This information can also be utilised to provide a rational basis for combination therapy with agents that target the cell cycle or to select patients that are more or less likely to respond to an RAR specific ligand.
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